Drug intelligence / Profile preview

SIR-T CLDN6

Development stage: Preclinical
Lead developer: Angeles Therapeutics
Modality: Cell Therapies
Administration: Intravenous

Overview

SIR-T CLDN6 is an engineered cell therapy candidate developed by Angeles Therapeutics, utilizing the proprietary Synthetic Immune Receptor (SIR-T) platform to target Claudin-6 (CLDN6). CLDN6 is an oncofetal antigen frequently overexpressed in solid tumors such as ovarian, lung, and testicular cancers, while remaining largely absent in healthy adult tissues. The SIR-T platform is designed to provide a more physiological T-cell activation signal compared to traditional CAR-T architectures, potentially enhancing persistence and reducing exhaustion. The program is currently in late preclinical development for the treatment of CLDN6-positive malignancies.

Other names: SIR-T Claudin-6

Targets

CLDN6 (Claudin-6)

Beyond the preview

Go deeper on SIR-T CLDN6.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SIR-T CLDN6.

Explore the full profile